Skip to main content

Terri Shieh-Newton, PhD

Member

[email protected]

+1.415.432.6084

Follow:
Share:

Dr. Shieh-Newton plays a strategic role for her clients as she guides their portfolio management and performs sophisticated landscape analyses. Trained as an immunologist at Johns Hopkins, where she earned a PhD in Cellular and Molecular Medicine, she works with companies of all sizes in a wide range of life sciences and clean technology industries. She also manages and conducts due diligence for companies and investors. Dr. Shieh-Newton is known for her creative, business-savvy solutions and collaborative work style.

Dr. Shieh-Newton has significant experience in a wide range of life sciences and clean technology industries that allows her to provide creative solutions and render business-savvy advice to her clients. Her practice focuses on patent strategy, comprehensive portfolio management, construction of valuable portfolios, preparation and prosecution of patent applications, interferences, and post-grant proceedings in the life sciences and clean technology sectors. She manages and conducts due diligences for both private and public companies and investors. Dr. Shieh-Newton has been the primary IP counsel on many deals on behalf of investment bankers and underwriters for IPOs and ATMs and other public offerings totaling hundreds of millions of dollars. Dr. Shieh-Newton has also worked on a number of reverse mergers and also represented companies on their securities disclosures for offerings in the capital markets. She has also worked with venture capitalists on due diligence assessment for investments and landscape analysis for formation of new funds and companies.

In addition, Dr. Shieh-Newton’s practice includes assessing freedom-to-operate positions and rendering patentability and invalidity opinions. She has extensive experience in evaluating patent landscapes to advise clients seeking to enter competitive markets, as well as advising clients on third party challenges and risk mitigation strategies. Dr. Shieh-Newton has worked on several biotechnology patent litigations.

Dr. Shieh-Newton has worked on a wide variety of technical areas including antibodies, biologics and biosimilars, immune-oncology (including chimeric T-antigen receptors), immunotherapy, stem cells, regenerative medicine, gene therapy, synthetic biology, microbiomes, enzymes, protein engineering, protein production and therapeutics, vaccines and adjuvants, diagnostics and biomarkers, cancer, biofuels, microbial engineering, industrial fermentation, production of target chemical using biological processes, and quantum sensors, amongst other subject matters.

Dr. Shieh-Newton has worked with emerging companies, universities, as well as larger companies. Representative matters include work done for DuPont/Danisco/Genencor, Regeneron, Roche, Genentech, Goodyear Rubber & Tire Company, Ariosa, University of California, Stanford University.

Dr. Shieh-Newton was trained as an immunologist at Johns Hopkins School of Medicine, where her doctoral research focused on the early immune responses to HIV and SIV infection. Dr. Shieh-Newton was a student fellow with Nobel Laureates Dr. Joseph Goldstein and Dr. Michael Brown, researching farnesylated ras proteins.

Education

  • Santa Clara University (JD, cum laude)
  • Johns Hopkins University (PhD, Cellular and Molecular Medicine)
  • Rice University (BA, Biochemistry)

Recognition & Awards

  • Recognized by The Legal 500 United States for Healthcare: Life Sciences (2019)

Recent Insights

News & Press

Events

News & Press

Mintz’s Terri Shieh-Newton shares her insights on gender equity, how to fix USPTO, and the most exciting thing in biotech today.
This feature story looks at a recent U.S. Patent and Trademark Office (USPTO) study; primarily focusing on the increased share of U.S. patents that include at least one woman as an inventor. This number has tripled in the last 30 years. In spite of this increase, the article goes on to note that female inventors still only make up slightly more than 10 percent of all inventors on U.S. patents granted in 2016. Mintz Member Terri Shieh-Newton is quoted providing commentary in the piece.

Mintz represents NuCana, which completed its approximately $114 million initial public offering. The United Kingdom-based clinical-stage company focuses on improving treatment outcomes for patients with cancer.

Subject Matter Eligibility Under 35 U.S.C. § 101 – Life Sciences

June 1, 2016

Terri Shieh-Newton, a Mintz Member, authored this IP Frontline column discussing the USPTO's issuance of a memorandum to the “Patent Examining Corps to provide further Examiner instructions relating to subject matter eligibility under 35 U.S.C. § 101.”  

Events

Moderator
Nov
1
2018

Wine & War Stories

Domenico Winery, 1697 Industrial Road, San Carlos, CA

Speaker
Oct
3
2018
Moderator
Oct
2
2018

Empowering Women Change-Makers in The Synthetic Biology Industry

Mission Bay Conference Center, San Francisco

Speaker
Oct
3
2017

SynBioBeta SF 2017

SynBioBeta

San Francisco, CA

Panelist
Jun
3
2015

Protecting Your IP in the Age of the Collaborative Economy

San Francisco Center for Economic Development

San Francisco, CA